1. Scrip
  2. >>Business

Alnylam Plans Lumasiran Phase III As Market Landscape Gets Competitive

 
• By John Davis

Alnylam will take on the global development and commercialization of investigational rare disease therapy lumasiran as Sanofi declines to opt-in to its development, and the US biotech prepares to commercialize its first RNAi therapeutic, pencilled in for later this year.  

Options
Choices have to be made between competing priorities. • Source: Shutterstock

Sanofi's decision not to opt-in to the development and commercialization of ultra-orphan therapy lumasiran is considered a positive for the product's originator, Alnylam Pharmaceuticals Inc., but there are concerns that the French firm has now declined options on several of Alnylam's investigational RNA interference (RNAi) products that might have supported the biotech as it prepares its strategy for the potential approval and launch of lead product, patisiran, for the treatment of hereditary ATTR amyloidosis, in mid-2018.

Alnylam, which now has global rights to lumasiran, has pledged to start Phase III trials with the primary

More from Deals

More from Business

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 
• By Sushmita Panda

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.